Skip to content

Efficacy of PRF Application on Clinical Parameters and GCF Platelet-derived Growth Factor-BB and Periostin Levels

The Efficacy of Application of Platelet-rich Fibrin on Periodontal Clinical Parameters and Gingival Crevicular Fluid Platelet-derived Growth Factor-BB and Periostin Levels

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05178771
Enrollment
14
Registered
2022-01-05
Start date
2022-03-01
Completion date
2022-09-25
Last updated
2022-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis

Keywords

PRF, PDGF-BB, Periostin

Brief summary

Determine the efficacy of the non-invasive application of PRF on periodontal clinical parameters(pocket reduction) and the levels of PDGF-BB and Periostin in the gingival crevicular fluid.

Detailed description

The adjunctive use of PRF with conventional ScRp may improve clinical healing, decrease tissue morbidities such as pain and discomfort, increase patient acceptance, reduce treatment time. Since PRF can be utilized as a safe, natural method to repair tissues at a low cost. Our aim is to evaluate the effectiveness of the non-invasive application of PRF as an adjunct to ScRp in patients with stage III grade B periodontitis through measurements of gingival crevicular fluid levels of PDGF-BB and Periostin before and after treatment and compare it with ScRp alone. A split-mouth procedure will be performed to reduce confounders as possible.

Interventions

OTHERPlatelet rich fibrin

1. Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes. 2. A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box. 3. The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions. 4. The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used. The PRF volume will be calculated by recording how many pieces will be inserted.

Sponsors

University of Baghdad
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

Randomization will be performed by coin toss method

Intervention model description

A split-mouth procedure will be formed. Two quadrants in each participant will be selected; the sites will be divided into two groups: control site( will treat by ScRp only) and test sites( will treat by ScRp and PRF)

Eligibility

Sex/Gender
ALL
Age
15 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Systemically healthy patients. * Patients with periodontitis.

Exclusion criteria

1. Medical history of systemic disease: diabetes, pregnancy, or lactation. 2. Previous periodontal treatment for the last 6 months 3. Grade II mobility 4. Smoker or alcoholic patient. 5. Teeth with untreated caries, endodontic lesions 6. Symptoms of recent acute illness e.g., COVID-19 will be excluded as well

Design outcomes

Primary

MeasureTime frameDescription
clinical parameters4 weeks and 3 monthsmeasurements of pocket depth in millimeter at baseline and at the end of study

Secondary

MeasureTime frameDescription
PDGF-BB and periostin level in GCF4 weeks and 3 monthsMeasurement of PDGF-BB and periostin level in GCF in baseline data and at the end of study

Countries

Iraq

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026